Review Article
Glycosaminoglycan Storage Disorders: A Review
Table 2
Available therapeutic approaches for mucopolysaccharidoses.
| | Pathology | Subtype | Available therapeutic approaches |
| | MPS I | Hurler (H) | HSCT (recommended before 2 years of age) | | Hurler -Scheie (H/S) | ERT with Aldurazyme (laronidase; recombinant human α-L-iduronidase) | | Scheie (S) | ERT with Aldurazyme (laronidase; recombinant human α-L-iduronidase) | | MPS II | Hunter | ERT with Elaprase (idursulfase; recombinant human iduronate sulfatase) | | MPS III | Sanfilippo A | Not available* | | Sanfilippo B |
*Not available* | | Sanfilippo C |
*Not available* | | Sanfilippo D |
*Not available* | | MPS IV | Morquio A | ERT: ongoing clinical trial (with recombinant human GALNS) | | Morquio B |
*Not available* | | MPS VI (Maroteaux-Lamy) | | ERT with Naglazyme (galsulfase; recombinant human arylsulfatase B) | | MPS VII (Sly) | |
*Not available* | | MPS IX | |
*Not available* |
|
|
